Kornimate/medical-research-clean huggingface dataset:
exclusive breastfeeding in infants of mothers infected with novel coronavirus

Conditions: Covid19; Breastfeeding, Exclusive; Newborn Morbidity

Summary: covid-19 pandemic emerges an issue for breastfeeding.earlier in pandemic mothers who had covid-19 were separated from their babies due to insufficient data but this approach was abandoned due to the lack of transmission via breastmilk.however, where mothers with covid-19 are cohorted in the same room, they still have to be isolated from their babies following the birth.investigators aimed to evaluate rate of exclusive breastfeeding(eb) within first 6 months among mothers who were isolated from their babies due to covid-19.

covid-19 pandemic emerges an issue for breastfeeding.earlier in pandemic mothers who had covid-19 were separated from their babies due to insufficient data but this approach was abandoned due to the lack of transmission via breastmilk.however, where mothers with covid-19 are cohorted in the same room, they still have to be isolated from their babies following the birth.to our knowledge, there is no study regarding this subject to-date.therefore, investigators aimed to evaluate rate of exclusive breastfeeding(eb) within first 6 months among mothers who were isolated from their babies due to covid-19.

Eligibility criteria:
inclusion criteria: * infants who were born to mothers with suspected or evident covid-19 * accepted to participate with an informed consent of parents exclusion criteria: * congenital abnormalities * chromosomal abnormalities * contraindication for breastfeeding * declined to participate
rituximab plus venetoclax in combination with zandelisib in subjects with cll

Conditions: CLL

Summary: a phase 2 study of zandelisib with venetoclax (ven) and rituximab (r) in subjects with relapsed/refractory cll.

this is an open label phase 2 clinical study of zandelisib with venetoclax (ven) and rituximab (r) in subjects with r/r cll. ven and r will be administered per standard of care. subjects must have histologically confirmed relapsed/refractory cll and received ≥1 lines of prior therapy a total 42 subjects will be enrolled and treated with zandelisib in combination with ven + r.

Eligibility criteria:
inclusion criteria: * males or females ≥18 years * histologically confirmed relapsed/refractory cll who received ≥1 lines of prior therapy * at least one bi-dimensionally measurable nodal lesion \>1.5 cm * adequate renal, hepatic function * adequate hematologic parameters at screening exclusion criteria: * subjects who relapsed or progressed on bcl-2 inhibitor * relapsed within 2 years of discontinuation of prior pi3k inhibitor (pi3ki) therapy or disease progression on pi3ki therapy * history or currently active hbv, hcv; any uncontrolled active infection, hiv infection; hiv-related lymphoma * history of richter's transformation or prolymphocytic leukemia * known allergies to both xanthine oxidase inhibitors and rasburicase, or any excipients of the drug products * currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure * pregnant women

Keywords: leukemia
covid-19 vaccine reactogenicity and immunogenicity

Conditions: COVID-19; Vaccine Immune Response; Vaccine Adverse Reaction

Summary: analysis of antibody kinetics after vaccination with mrna-1273 and factors influencing the vaccine immunogenicity

we conducted a prospective study on healthy young adults who were to receive two doses of mrna-1273 vaccine at 28-day intervals. after each dose, adverse events were prospectively evaluated, and blood samples were collected. the correlation between humoral immune response and reactogenicity after vaccination was determined. in addition, long-term anti-sars-cov-2 antibody kinetics will be assessed.

Eligibility criteria:
inclusion criteria: * who were willing to receive the mrna-1273 vaccine exclusion criteria: * previously diagnosed with laboratory-confirmed covid-19 * history of autoimmune disease * immunocompromised, pregnant, or breastfeeding
feasibility study of platelet activation and inflammatory response of platelets in hematopoietic stem cell allograft patients post-transplant: spontaneously and after stimulation by an cmv antigen

Conditions: Allograft

Summary: traditionally known for their role in haemostasis, platelets have also an immune role. platelets play a key role in immune mediator secretion, and interact with innate and adaptive immune cells, contributing to the fight against pathogens, as viruses. cytomegalovirus (cmv) is responsible of allograft patients' serious infections, because of the induced immune depression. platelets activation for patients is not determined during the post-graft period, and platelet induced inflammation following a cmv infection is not described.

the descriptive present study will determine if platelet activation is altered during the post-graft follow-up (day 30 to 90). the activation will be studied spontaneously and after simulation by a cmv (cytomegalovirus) antigen. the study will also focus on inflammatory response variation, focusing on the cytokines release during the same post-graft follow-up (spontaneously and after cmv antigen stimulation). this preliminary study could lead to a better understanding of the immune-modulator role of inflammation, controlled by the platelets, particularly in the initiation of the graft-versus-host disease in this kind of population.

Eligibility criteria:
inclusion criteria: * patients who received an allogeneic haematopoietic stem cell transplant for less than 2 months for any indication ; * platelets \> 20 g / l (giga per litre) for at least 7 days without transfusion support ; * patients affiliated to a social security scheme. exclusion criteria: * patients receiving antiplatelet therapy ; * major protected or unable to give consent ; * pregnant women ; * vulnerable persons defined by french legislation.

Keywords: allograft cytomegalovirus platelets hematopoietic stem cells graft versus host disease (gvh) hemostasis adaptive immunity innate immunity post graft follow up
isentress re-examination study (mk-0518-115)

Conditions: HIV Infection; HIV Infections

Summary: this survey is conducted for preparing application materials for re-examination under the pharmaceutical affairs laws and its enforcement regulation, its aim is to reconfirm the clinical usefulness of isentress through collecting the safety and efficacy information in usual practice according to the re-examination regulation for new drugs. post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. the results will be submitted to public health officials as required by applicable national and international laws.


Eligibility criteria:
inclusion criteria: * hiv-1 infected adults * treated with isentress 400 mg tablet within local label during the enrollment period exclusion criteria: * contraindication to isentress according to the local label
years score vs ctpa in pulmonary embolism

Conditions: Pulmonary Embolism

Summary: the investigators' aim in this study is to assess the sensitivity and accuracy of years algorithm in the diagnosis of pe.

pulmonary embolism (pe) is a relatively common acute cardiovascular disorder with high early mortality rates that, despite advances in diagnosis and treatment over the past 30 years, have not changed significantly. due to pulmonary bed obstruction, pe can result in acute right ventricular (rv) failure. because most patients ultimately die within the first hours of presentation, early diagnosis is of paramount importance. the incidence of pe is estimated to be approximately 60 to 70 per 100,000, and that of venous thrombosis approximately 124 per 100,000 of the general population. because of its diagnostic accuracy and wide availability, multidetector row computed tomography pulmonary angiography (ctpa) is the imaging test of choice to confirm acute pulmonary embolism in most patients. increasing use of ctpa with diminishing prevalence of pulmonary embolism to even less than 10% has led to overdiagnosis of mostly subsegmental pulmonary embolism and unnecessary risks of radiation exposure and contrast medium induced nephropathy. to avoid these problems, validated diagnostic algorithms for suspected acute pulmonary embolism, using sequential testing, have been introduced. in these algorithms, a normal d-dimer test result in patients with low probability safely excludes pulmonary embolism. years scoring system is an algorithm to predict diagnosis of pulmonary embolism according to clinical signs and d-dimer. the aim of this study is to test predictive accuracy, sensitivity and specificity of years score compared to ctpa in the diagnosis of pe as ctpa is an invasive procedure, expensive and not readily available in many settings, thus, finding an alternative easier method that can diagnose pe may help save the time and resources.

Eligibility criteria:
inclusion criteria: * any patient more than 18 years old presenting to the emergency room with symptoms of clinically suspected pulmonary embolism such as: * sudden onset of dyspnea, sudden deterioration of existing dyspnea, sudden onset of pleuritic chest pain without another apparent cause. * any other symptoms like hemoptysis, syncope or unilateral leg pain. exclusion criteria: * pregnancy * allergy to intra-venous contrast agents * renal insufficiency (creatinine clearance \< 30 ml/min).
heads up messages to increase call pick-up rates

Conditions: Various: Health Insurance Members That Could Benefit From Being Connected to a Specialist, e.g., Orthopedic Doctor to Treat Back Pain

Summary: the study aims to investigate whether notifying health insurance members about an upcoming call can increase their pick-up rates. the study will randomize participants into three groups: control group (no message), treatment group 1 (message variation 1), and treatment group 2 (message variation 2). the primary outcome of interest is the call pick-up rate, and the study will also examine the message opt-out rates for the two different messages.


Eligibility criteria:
inclusion criteria: * the study will include members enrolled in the health insurers' relay texting system due to receive an outreach call during the study timeframe. * enrollment in the study will end when we meet our enrollment target (n=2000)
safety and efficacy of γδ t cell against gastric cancer

Conditions: Gastric Cancer

Summary: in this study, safety and effects of γδt cells on human gastric cancer are going to be investigated.

pbmc of the patient will be separated from peripheral blood. after making them potential cancer killer γδ t cell and cik, they will be infused to the patients as immunotherapy.

Eligibility criteria:
inclusion criteria: 1. age:30-75 2. karnofsky performance status \>50 3. diagnosis with gastric cancer based on histology or the current accepted radiological measures. 4. classification tumor,nodes,metastasis-classification(tnm) stage: ⅱ,ⅲ,ⅳ 5. patients who have a life expectancy of at least 12 weeks 6. ability to understand the study protocol and a willingness to sign a written informed consent document exclusion criteria: 1. any significant medical or psychiatric illness that would prevent the patient from giving informed consent or from following the study procedures. 2. known human immunodeficiency virus (hiv) infection. 3. active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic infections, active hepatitis b virus (hbv) or active hepatitis c virus (hcv) infection). 4. other serious underlying medical conditions, which, in the investigator's judgment, could impair the ability of the patient. 5. pregnancy
promoting sustainable return to work among employees on sick leave due to a mental health condition: evaluation of the healthyminds online group intervention

Conditions: Depression Anxiety Disorder; Adjustment Disorders; Adjustment Disorder With Anxious Mood; Adjustment Disorder With Depressed Mood

Summary: the purpose of this clinical trial is to evaluate the impact of an online group intervention called healthy minds in facilitating a sustainable return to work for individuals with a mood disorder. the study aims to answer the following key questions : * does receiving the healthy minds online intervention lead to a more sustainable return to work compared to not receiving the intervention? * are the health outcomes (e.g., depressive symptoms) and work-related outcomes (e.g., work functioning) of individuals who receive the healthy minds online intervention better than those who do not receive the intervention in the year following the intervention? both experimental and control participants will be recruited at baseline while on sick leave (expected to return to work in less than one month) or recently returned to work (less than one month). participants will complete a series of online questionnaires at the following time points : * baseline * first follow-up (2 months after baseline) * second follow-up (6 months after baseline) * third follow-up (12 months after baseline) the questionnaires will cover the following areas : * sociodemographic and biopsychosocial factors * symptoms associated with the primary mood disorder * cognitive difficulties and biaises * self-efficacy related to return to work * work accommodations and natural supports * relationship with immediate supervisor * work functioning * return to work time (number of days away from work) experimental participants will participate in the 2-month online healthy minds group intervention (cohort of 5 participants) between the baseline assessment and the first follow-up. the intervention consists of 8 sessions (one per week for 8 weeks), with each session focusing on a specific aspect of the return-to-work process from a cognitive-behavioral perspective.


Eligibility criteria:
inclusion criteria: * be in the process of returning to work after depression, anxiety disorder, adjustment disorder (with depressed mood, or anxious mood). or * been back for less than a month exclusion criteria: * inability to communicate in french * have a known organic disorder * have already received cbt-type intervention (group or individual)
effect of clonazepam on rem sleep behavior disorder in patients with parkinsonism

Conditions: REM Sleep Behavior Disorder

Summary: the purpose of this study is to determine whether clonazepam is effective and safe in the treatment of rapid eye movement behavior disorder (rbd) of patients with parkinson's disease (pd).

rbd is one of the representative non-motor symptoms of pd and other synucleinopathies. patients with rbd show dream-enacting behaviors such as punching, kicking, singing, screaming, or somnambulism. these can interfere in sleep quality and increase the risk of falling down from the bed and physical injuries of both the patient and sleep partner. therefore, qualities of life of the patient and sleep partner are negatively influenced by presence of rbd. clonazepam has been used for treatment of choice of rbd. it decreased rbd symptoms completely in 55-79% and partially in 11-32% of patients. however, these results are based on open-label or descriptive studies. there has been no randomized placebo controlled study that evaluated the efficacy and safety of clonazepam for treating rbd.

Eligibility criteria:
inclusion criteria: * subject was enrolled voluntarily and understood the contents of this clinical trial * subject was diagnosed as parkinson disease (pd) or parkinson's syndrome * hoehn and yahr (h\&y) stage 1, 2, or 3 * existence of caregivers who can provide a information about symptoms of rapid eye movement sleep disorder (rbd) of the participant * existence of rbd by answering "yes" to the question (rbd-1q): "have you ever been told, or suspected yourself, that you seem to 'act out your dreams' while asleep (for example, punching, flailing your arms in the air, making running movements, etc.)?" exclusion criteria: * existence of cognitive decline hard to participate in the clinical trial * subject has confusion or visual hallucination in daytime * diagnosed as obstructive sleep apnea or severe snoring * previous clonazepam treatment within 4 weeks * current treatment with benzodiazepines at bedtime * alcoholics or drug abuser * lactating, pregnant, or possible pregnant * hypersensitivity to clonazepam or benzodiazepines * prior participation to other clinical trials within 3 months * presence of severe comorbidities or a cancer * existence of illness or problems which makes difficult to be enrolled to this trial judged by clinicians

Keywords: rem sleep behavior disorder parkinson disease placebos randomized controlled trial double-blind method clinical trial
signaling pathways targeting colorectal cancer in egypt

Conditions: Colorectal Cancer

Summary: colorectal cancer (crc) is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. in egypt, crc constitutes 4.2% of all cancers with median age is 50 years old.

the tp53-induced glycolysis and apoptosis regulator (tigar) is a transcriptional target of p53. tigar functions as a fructose-2,6-bisphosphatase, decreasing the flux through the main glycolytic pathway. consequently, glucose metabolism diverted into the pentose phosphate pathway (ppp). this results in tigar-mediated increase in cellular nadph production, which contributes to the scavenging of ros by reduced glutathione and thus a lower sensitivity of cells to oxidative stress-associated apoptosis. ppp also produce ribose phosphate for dna synthesis and repair that play a role in tumor development and cell survival in tumor microenvironment. a high expression level of tigar was observed in cancers such as breast cancer, hepatocellular carcinoma, intestinal cancer, and glioblastoma. these studies suggested that tigar may act as an oncogene that support cancer progression. the tripartite motif containing 59 (trim) proteins have been implicated in many biological processes including cell differentiation, apoptosis, transcriptional regulation, and signaling pathways. it is related to several cancers. the oncogenic effect of trim59 on tumor proliferation and migration has been studied in various cancers, including gastric cancer, osteosarcoma, lung and crc. the biological activity of trim59 has been observed to be closely associated with the regulation of p53. trim59 interacts with p53, leading to p53 ubiquitination and degradation, and consequently promotes tumor growth and migration. trim59 functions as an oncogene in crc progression. it also activates the pi3k/akt pathway. increased activity of this pathway is often associated with tumor progression and resistance to cancer therapies. akt can control tigar protein translation by activation of mtor. targeting trim59 inhibition will inhibit pi3k-akt pathway downregulate tigar protein translation. this is in turn downregulates gsh levels, increases ros production, leading to cell death and blocks the cellular proliferation and survival of cancer cells leading to tumor regression. therefore, trim59 protein can serve as a new potential therapeutic target for crc.

Eligibility criteria:
inclusion criteria: * all patients confirmed histopathologically to have early stages of colorectal cancer. * risky group patients (including those with ulcerative colitis, chron's disease, familial adenomatous polyposis). exclusion criteria: * patients with previous history of crc treated with chemotherapy or presence of other types of cancer.

Keywords: colorectal cancer tigar trim59
ccsv - post market clinical follow-up study

Conditions: Cardiac Arrest

Summary: the main goal of this observational study is the evaluation of chest compression synchronized ventilation (ccsv) regarding oxygenation in terms of pao2 assessed by routine blood gas analysis, hemodynamic effects, 30-day outcome and safety in comparison to intermittent positive pressure ventilation (ippv) as data in humans is sparse especially in direct comparison to other ventilation modes. cardiac arrest patients in vienna, austria will be preclinically randomized (ippv and ccsv) and ventilated accordingly during cpr. differences in oxygenation, decarboxylation, systemic perfusion and cerebral oxygenation, the patient's 30-day outcome as well as ventilator-associated adverse events (e.g., pneumothorax) will be recorded and analyzed.


Eligibility criteria:
inclusion criteria: * ohca * correct endotracheal intubation (seen by capnography) * the patient is being treated by the vienna emergency medical services within the scope of emergency ventilation. * medumat standard from weinmann emergency is used. * mechanical ventilation is performed according to the specified indications. exclusion criteria: * patients eligible for ecpr (as defined by the standard operating procedure of the emergency medical service vienna) * patients recovering (reaching sustained rosc) before starting mechanical ventilation or in the first three minutes of it * any other mechanical ventilation during the ongoing cpr before study inclusion * traumatic cardiac arrest * suspected or known pregnancy * clinically suspected (tension-)pneumothorax
validation of an ai-assisted mediastinal eus system for training improvement: a prospective, multi-center, randomized trial

Conditions: Mediastinal Disease

Summary: the goal of this clinical trial is to verify the auxiliary role of the artificial intelligence (ai) system in mediastinal endoscopic ultrasound (eus) scans. the main questions it aims to answer are as follows: 1. a comparison of the image recognition accuracy between the ai system and eus endoscopists. 2. whether the ai system can improve the quality of mediastinal scans for eus endoscopists. participants will conduct mediastinal eus with or without the assistance of the ai system.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years old, \<80 years old 2.patients who need endoscopic ultrasonography; 3. agree to participate in this study and sign the informed consent form. exclusion criteria: subjects who meet any of the following criteria cannot be selected for this trial: first. the patient's physical condition does not meet the requirements of conventional endoscopic ultrasonography: poor physical condition, including hemoglobin ≤8.0g/dl, severe cardiopulmonary insufficiency, etc. anesthesia assessment failed pregnancy or breastfeeding in the acute stage of chemical and corrosive injury, it is very easy to cause perforation recent acute coronary syndrome or clinically unstable ischemic heart attack heart disease patients with right-to-left shunt, patients with severe pulmonary hypertension (pulmonary artery pressure\> 90mmhg), patients with uncontrolled systemic hypertension and patients with adult respiratory distress syndrome. second. disagree to participate in this study. third. there are other problems that do not meet the requirements of this research or that affect the results of the research: 1. mediastinal lesions have previously undergone surgery or radiotherapy and chemotherapy; 2. mental illness, drug addiction, inability to express themselves or other diseases that may affect follow-up.